Oncology

Snippets - A Small piece of News or Article

Harmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma

Date of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemo-immunotherapy. The CELMoD agents, exemplified by GOLCA, demonstrate potent capabilities in degrading target proteins Ikaros/Aiolos, leading to a multifaceted impact characterized by antiproliferative, apoptotic, and immunomodulatory activities. As per the results presented at the ASH 2023 conference, there were 71 patien...

Explore More...

Pharma News and Updates for AbbVie, Ferring, Merck, CSL, Amicus, Takeda

Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

Bispecific Antibodies in DLBCL, Opportunities and Challenges

Olympus Launches New Gynecologic Power Morcellator; Journey Biosciences Launched NaviDKD; GE Board Approves Separation of GE HealthCare; FDA Approval to Enovis’s STAR Ankle; FDA Clearance to Deep Blue Medical’s T-Line Hernia Mesh; NeuroOne Completed Feasibility Study with its OneRF Ablation System

Pharma News for Nkarta, Eisai, EQRx, Rigel Pharma, AUM, X4 Pharma

Nkarta’s Anti-CD19 Allogeneic CAR-NK Cell Therapy, NKX019; Eisai Presents Results of lecanemab for Alzheimer’s Disease; EQRx’s Aumolertinib for EGFR-Mutated NSCLC; FDA Approves Olutasidenib for IDH1-Mutated R/R AML; FDA Orphan Drug Designation to AUM302 for Neuroblastoma; X4 Pharma Announces Results for WHIM Syndrome Drug

pd-and-pd-l1-inhibitors-in-cancer-treatment

PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?

MedTech News Updates for AnchorDx, UroMems, NeuroLogica, Ypsomed

AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery

Antibody Drug Conjugates for Cancer Treatment in Asia Healthcare Market

FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

RNA Interference: New Class of Drugs In The Fight Against Disease

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Oncology

Harmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma

Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges

ASH 2022: Preview of the Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market

ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL

ASH 2022: Yescarta emerging as the CAR-T leader in DLBCL; Failure of Kymriah in early lines of DLBCL

ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs

More Views & Analysis

PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?

Antibody-Drug Conjugate: The Smart Biological Bomb

Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market

ESMO Asia 2022: Role of EGFR and ALK mutations in the East Asian Lung Cancer Market

FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

RNA Interference: New Class of Drugs In The Fight Against Disease

Gene Therapy: The Next Milestone in Treating Complex Diseases

Subscribe to our Updates

Daily

Weekly

Monthly